Cargando…

Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism

Single nucleotide polymorphisms (SNPs) reportedly influence the effect of nivolumab in metastatic renal cell carcinoma (mRCC). This study aimed to evaluate the relationship between the clinical outcomes of patients with mRCC and SNPs in programmed cell death protein 1 (PD-1) protein-coding gene (PDC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Mizuki, Numakura, Kazuyuki, Hatakeyama, Shingo, Muto, Yumina, Sekine, Yuya, Sasagawa, Hajime, Kashima, Soki, Yamamoto, Ryohei, Koizumi, Atsushi, Nara, Taketoshi, Saito, Mitsuru, Narita, Shintaro, Ohyama, Chikara, Habuchi, Tomonori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324515/ https://www.ncbi.nlm.nih.gov/pubmed/35885987 http://dx.doi.org/10.3390/genes13071204

Ejemplares similares

Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma
por: Numakura, Kazuyuki, et al.
Publicado: (2023)

First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology
por: Numakura, Kazuyuki, et al.
Publicado: (2020)

Factors influencing warm ischemia time in robot-assisted partial nephrectomy change depending on the surgeon’s experience
por: Numakura, Kazuyuki, et al.
Publicado: (2022)

Robot-assisted laparoscopic pyeloplasty for ureteropelvic junction obstruction with duplex system
por: Numakura, Kazuyuki, et al.
Publicado: (2020)

Specific Gut Microbial Environment in Lard Diet-Induced Prostate Cancer Development and Progression
por: Sato, Hiromi, et al.
Publicado: (2022)

BRCA2 Frameshift Mutation in de novo Small-Cell Neuroendocrine Carcinoma of the Prostate: A Case Report
por: Okubo, Keisuke, et al.
Publicado: (2023)

Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab
por: Takahashi, Shuhei, et al.
Publicado: (2022)

Altering phosphoinositides in high‐fat diet‐associated prostate tumor xenograft growth
por: Huang, Mingguo, et al.
Publicado: (2021)

Overweight Patients Less Improved Kidney Function After Laparoscopic Surgery for Adrenocortical Adenoma With Excess Cortisol Secretion
por: Numakura, Kazuyuki, et al.
Publicado: (2019)

Macrophage inhibitory cytokine‐1 induced by a high‐fat diet promotes prostate cancer progression by stimulating tumor‐promoting cytokine production from tumor stromal cells
por: Huang, Mingguo, et al.
Publicado: (2021)

The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer
por: Numakura, Kazuyuki, et al.
Publicado: (2023)

Prognostic value of plasminogen activator inhibitor‐1 in biomarker exploration using multiplex immunoassay in patients with metastatic renal cell carcinoma treated with axitinib
por: Honma, Naoko, et al.
Publicado: (2020)

Incidence, Etiology, Prevention and Management of Ureteroenteric Strictures after Robot-Assisted Radical Cystectomy: A Review of Published Evidence and Personal Experience
por: Narita, Shintaro, et al.
Publicado: (2021)

Insulin-like growth factor-1 genotypes and haplotypes influence the survival of prostate cancer patients with bone metastasis at initial diagnosis
por: Tsuchiya, Norihiko, et al.
Publicado: (2013)

Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer
por: Sato, Hiromi, et al.
Publicado: (2018)

Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer
por: Matsuda, Yoshinori, et al.
Publicado: (2020)

Complete remission of brain metastases in renal cell carcinoma treated with axitinib after failure with nivolumab and ipilimumab treatment
por: Takayama, Koichiro, et al.
Publicado: (2022)

The impact of obesity and adiponectin signaling in patients with renal cell carcinoma: A potential mechanism for the “obesity paradox”
por: Ito, Ryuichi, et al.
Publicado: (2017)

Research Evidence on High-Fat Diet-Induced Prostate Cancer Development and Progression
por: Narita, Shintaro, et al.
Publicado: (2019)

Fatty acid binding protein 4 enhances prostate cancer progression by upregulating matrix metalloproteinases and stromal cell cytokine production
por: Huang, Mingguo, et al.
Publicado: (2017)

Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma
por: Okuyama, Yoshiharu, et al.
Publicado: (2021)

Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma
por: Tsuchiya, Norihiko, et al.
Publicado: (2014)

Successful mammalian target of rapamycin inhibitor maintenance therapy following induction chemotherapy with gemcitabine and doxorubicin for metastatic sarcomatoid renal cell carcinoma
por: NUMAKURA, KAZUYUKI, et al.
Publicado: (2014)

Characterization of Clinical and Genetic Risk Factors Associated with Dyslipidemia after Kidney Transplantation
por: Numakura, Kazuyuki, et al.
Publicado: (2015)

Effects of NR1I2 and ABCB1 Genetic Polymorphisms on Everolimus Pharmacokinetics in Japanese Renal Transplant Patients
por: Yagishita, Hironobu, et al.
Publicado: (2022)

Successful Local Control of Recurrent Penile Cancer Treated with a Combination of Systemic Chemotherapy, Irradiation, and Mohs’ Paste: A Case Report
por: Komine, Naoki, et al.
Publicado: (2014)

Host-related Risk Factors for Adherent Perinephric Fat in Healthy Individuals Undergoing Laparoscopic Living-donor Nephrectomy
por: Narita, Shintaro, et al.
Publicado: (2017)

Cytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model
por: Kashima, Soki, et al.
Publicado: (2020)

Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients
por: Kagaya, Hideaki, et al.
Publicado: (2018)

Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer
por: Narita, Shintaro, et al.
Publicado: (2012)

Secondary bladder amyloidosis with familial Mediterranean fever in a living donor kidney transplant recipient: a case report
por: Imamura, Sentaro, et al.
Publicado: (2016)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
por: Numakura, Kazuyuki, et al.
Publicado: (2021)

Subsequent Upper Urinary Tract Carcinoma Related to Worse Survival in Patients Treated with BCG
por: Numakura, Kazuyuki, et al.
Publicado: (2023)

Capability of Utilizing CYP3A5 Polymorphisms to Predict Therapeutic Dosage of Tacrolimus at Early Stage Post-Renal Transplantation
por: Niioka, Takenori, et al.
Publicado: (2015)

Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients
por: Numakura, Kazuyuki, et al.
Publicado: (2018)

Therapeutic effects of the combined androgen blockade therapy versus luteinizing hormone-releasing hormone analog monotherapy in patients with hormone naïve metastatic prostate cancer: a multi-institutional comparative analysis
por: Narita, Takuma, et al.
Publicado: (2021)

Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi-institutional retrospective study
por: Kato, Renpei, et al.
Publicado: (2022)

Correction to: Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi‑institutional retrospective study
por: Kato, Renpei, et al.
Publicado: (2023)

Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma
por: Hagimoto, Hiroki, et al.
Publicado: (2020)

Clinical impact of early response to first‐line VEGFR‐TKI in patients with metastatic renal cell carcinoma on survival: A multi‐institutional retrospective study
por: Sobu, Ryuta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eh6tqq0r7rle4a52vif36i2jf1